Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-210-6248
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees7
Next Earnings DateN/A
OptionableNot Optionable
MOTIF BIO PLC/S (NASDAQ:MTFB) Frequently Asked Questions
What is MOTIF BIO PLC/S's stock symbol?
MOTIF BIO PLC/S trades on the NASDAQ under the ticker symbol "MTFB."
What price target have analysts set for MTFB?
2 Wall Street analysts have issued 1 year price objectives for MOTIF BIO PLC/S's stock. Their forecasts range from $5.00 to $32.00. On average, they expect MOTIF BIO PLC/S's share price to reach $18.50 in the next year. This suggests a possible upside of 910.9% from the stock's current price. View Analyst Price Targets for MOTIF BIO PLC/S.
What is the consensus analysts' recommendation for MOTIF BIO PLC/S?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MOTIF BIO PLC/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MOTIF BIO PLC/S.
What are Wall Street analysts saying about MOTIF BIO PLC/S stock?
Here are some recent quotes from research analysts about MOTIF BIO PLC/S stock:
- 1. Northland Securities analysts commented, "We anticipate the Co. to provide guidance on iclaprim’s path forward in June. Key Points Motif Completes $3.55MM Raise: Pre-open, Motif announced that it has completed placement of 45MM ordinary shares priced at 6 pence, raising gross proceeds of £2.7MM (~$3.55MM USD) providing the Company with additional working capital. The offering, if translated into ADS equivalents, would approximate 2.5MM ADS shares at $1.58 per share. Through FDA Update: The net proceeds from the offering, combined with existing cash resources, and adjusted for repayment of $0.5MM to Hercules Capital, approximate $5- $5.5MM. We anticipate cash balances to be sufficient to fund operations beyond its receipt of minutes anticipated in early-June from the May 3rd Type A meeting with the FDA." (3/26/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We employ a risk- adjusted net present value (rNPV) approach that yields $600M for iclaprim—with a 90% probability of success, 16% discount rate and 40% effective tax rate—and a price per share of $32.00 based on about 19M American Depositary Shares (ADSs) outstanding as of mid-2019." (8/14/2018)
Has MOTIF BIO PLC/S been receiving favorable news coverage?
News headlines about MTFB stock have been trending negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. MOTIF BIO PLC/S earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the stock's share price in the near future.
Who are some of MOTIF BIO PLC/S's key competitors?
Some companies that are related to MOTIF BIO PLC/S include Spring Bank Pharmaceuticals (SBPH), Imprimis Pharmaceuticals (IMMY), Selecta Biosciences (SELB), Alpine Immune Sciences (ALPN), Sierra Oncology (SRRA), ASLAN PHARMACEU/ADR (ASLN), Vernalis (VNLPY), Cumberland Pharmaceuticals (CPIX), Zafgen (ZFGN), Unum Therapeutics (UMRX), Verastem (VSTM), DURECT (DRRX), Processa Pharmaceuticals (PCSA), Catalyst Biosciences (CBIO) and China SXT Pharmaceuticals (SXTC).
What other stocks do shareholders of MOTIF BIO PLC/S own?
Who are MOTIF BIO PLC/S's key executives?
MOTIF BIO PLC/S's management team includes the folowing people:
- Dr. Graham George Lumsden, CEO & Exec. Director (Age 59)
- Mr. Jonathan E. Gold, CFO & Exec. Director (Age 46)
- Dr. David B. Huang, Chief Medical Officer (Age 44)
- Mr. Robert Dickey IV, Advisor (Age 63)
- Laurie Doyle, Head of Investor Relations & Corp. Communications
When did MOTIF BIO PLC/S IPO?
(MTFB) raised $17 million in an initial public offering (IPO) on Friday, November 18th 2016. The company issued 2,400,000 shares at $6.98 per share. H.C. Wainwright & Co. acted as the underwriter for the IPO.
Who are MOTIF BIO PLC/S's major shareholders?
MOTIF BIO PLC/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.13%).
Which institutional investors are buying MOTIF BIO PLC/S stock?
MTFB stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
How do I buy shares of MOTIF BIO PLC/S?
Shares of MTFB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MOTIF BIO PLC/S's stock price today?
One share of MTFB stock can currently be purchased for approximately $1.83.
How big of a company is MOTIF BIO PLC/S?
MOTIF BIO PLC/S has a market capitalization of $27.13 million. The company earns $-13,980,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. MOTIF BIO PLC/S employs 7 workers across the globe.
What is MOTIF BIO PLC/S's official website?
How can I contact MOTIF BIO PLC/S?
MOTIF BIO PLC/S's mailing address is 125 Park Avenue 25th Floor, New York NY, 10011. The company can be reached via phone at 212-210-6248 or via email at [email protected]
MarketBeat Community Rating for MOTIF BIO PLC/S (NASDAQ MTFB)
MarketBeat's community ratings are surveys of what our community members think about MOTIF BIO PLC/S and other stocks. Vote "Outperform" if you believe MTFB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTFB will underperform the S&P 500 over the long term. You may vote once every thirty days.
